news

Dectin-1 pathway may be crucial for treating fungal inflammation and pain

Researchers have identified the dectin-1 pathway as being a potential target for the treatment of pain associated with candidiasis…

candidiasis

Researchers from Osaka University identified how the Dectin-1 to TRP channel pathway is a signalling mechanism in the onset of pain, and how inhibition of the VNUT ATP transporter blocks candidiasis-mediated pain.

Candidiasis, candida albicans infection, can cause skin, genital or oral pain. Many studies have attempted to understand the source of pain in the condition, however none have provided a clear explanation.

The research team investigated the role of Dectin-1, a β-glucan receptor, in sensing fungal infection. They found that Dectin-1 was critical for the onset of pain related to fungal infection.

 

Access your FREE copy

 


Biomarkers aren’t just supporting drug discovery – they’re driving it

FREE market report

From smarter trials to faster insights, this report unpacks the science, strategy and real-world impact behind the next generation of precision therapies.

What you’ll unlock:

  • How biomarkers are guiding dose selection and early efficacy decisions in complex trials
  • Why multi-omics, liquid biopsy and digital tools are redefining the discovery process
  • What makes lab data regulatory-ready and why alignment matters from day one

Explore how biomarkers are shaping early drug development

Access the full report – it’s free!

 

The infection occurs frequently in patients who are immunocompromised or have poorly controlled diabetes. It affects a large proportion of women and causes vulvovaginal pain in around 75 percent of women worldwide, at some point in their lifetimes. The infection also causes severe nipple pain in some lactating women. The primary effective treatment has been the resolution of the infection, which may not occur quickly.

“We previously found that fungal infection stimulated pain through β-glucan nociceptors, such as Dectin-1, but we did not know whether these receptors directly interacted with Candida fungi,” said Assistant Professor Kenta Maruyama, lead author on the study. “We were excited to find that β-glucan–induced pain is abolished in Dectin-1 and TRPV1/TRPA1 deficient mice.”

The researchers also found that β-glucan stimulates nociceptors via the Dectin-1-PLC axis and activates neurons. Components secreted from the fungal cells caused the same activation of nociceptors.

“Our analyses revealed that β-glucan-induced allodynia (pain) is dependent on extracellular ATP and VNUT, an ATP transporter,” says Prof Maruyama. “We found that the VNUT inhibitor clodronate can be used to treat β-glucan-induced allodynia.”

The researchers have shown that this particular signalling pathway can be targeted as the activation of this pathway is critical for fungal inflammation and pain. Clodronate may be a readily available therapy that could be quickly adopted for the treatment of fungal pain.

The study was published in iScience.

Leave a Reply

Your email address will not be published. Required fields are marked *